185 related articles for article (PubMed ID: 29246238)
1. Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant.
Banan R; Christians A; Bartels S; Lehmann U; Hartmann C
Acta Neuropathol Commun; 2017 Dec; 5(1):98. PubMed ID: 29246238
[No Abstract] [Full Text] [Related]
2. Molecular analysis of diffuse intrinsic brainstem gliomas in adults.
Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M
J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation in pediatric high-grade gliomas.
Fassan M; Tassone E; Onisto M; Perilongo G; D'Avella D; Gardiman MP
Childs Nerv Syst; 2011 Jan; 27(1):7-8. PubMed ID: 21052697
[No Abstract] [Full Text] [Related]
4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
5. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
6. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
7. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
9. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
[TBL] [Abstract][Full Text] [Related]
10. Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors.
Sardi I; Cetica V; Massimino M; Buccoliero AM; Giunti L; Genitori L; Aricò M
Oncol Rep; 2009 Oct; 22(4):773-9. PubMed ID: 19724855
[TBL] [Abstract][Full Text] [Related]
11.
Kong Z; Lin Y; Jiang C; Li L; Liu Z; Wang Y; Dai C; Liu D; Qin X; Wang Y; Liu Z; Cheng X; Tian J; Ma W
Cancer Imaging; 2019 Aug; 19(1):58. PubMed ID: 31426864
[TBL] [Abstract][Full Text] [Related]
12. MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
Horbinski C; McCortney K; Stupp R
Neuro Oncol; 2021 May; 23(5):858-860. PubMed ID: 33830235
[No Abstract] [Full Text] [Related]
13. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
[TBL] [Abstract][Full Text] [Related]
14. Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma.
Zhang Y; Zhu J
Oncol Rep; 2019 Feb; 41(2):908-916. PubMed ID: 30535433
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Ishii D; Natsume A; Wakabayashi T; Hatano H; Asano Y; Takeuchi H; Shimato S; Ito M; Fujii M; Yoshida J
Neurol Med Chir (Tokyo); 2007 Aug; 47(8):341-9; discussion 350. PubMed ID: 17721049
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
17. Lack of MGMT promoter hypermethylation in hemangiopericytomas of the central nervous system.
Brokinkel B; Peetz-Dienhart S; Keyvani K; Stummer W; Paulus W; Hasselblatt M
J Neurooncol; 2012 Nov; 110(2):303-4. PubMed ID: 22915192
[No Abstract] [Full Text] [Related]
18. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
19. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
Hegi ME; Stupp R
Neuro Oncol; 2015 Nov; 17(11):1425-7. PubMed ID: 26374690
[No Abstract] [Full Text] [Related]
20. Status of O⁶ -methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India.
Nehru GA; Pai R; Samuel P; Chacko AG; Chacko G
Neurol India; 2012; 60(5):481-6. PubMed ID: 23135024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
